

NOVA WELLNESS GROUP BERHAD

(the “Company”)

(Registration No. 201601025155 (1196094-M))

(Incorporated in Malaysia)

Minutes of the Fifth Annual General Meeting of the Company held virtually through live streaming via a remote participation and voting facilities at the Broadcast Venue at Conference Room, Nova Laboratories Sdn. Bhd., Lot 708, Nova Avenue, 43950 Sungai Pelek, Selangor Darul Ehsan, Malaysia on Tuesday, 16 November 2021 at 10.00 a.m.

Present : **Board of Directors**
Dr Abdul Manaf Bin Mohamad Radzi - Independent Non-Executive Chairman
Phang Nyie Lin - Managing Director
Phang Yeen Nung - Executive Director
Phang Yeen Aun - Executive Director
Sulaiman Bin Haji Ahmad - Non-Independent Non-Executive Director
Sim Seng Loong @ Tai Seng - Independent Non-Executive Director
Tan Mio Har - Independent Non-Executive Director

Shareholders

- As per attendance list

Proxies

- As per attendance list

Invitees

- As per attendance list

In Attendance : Ms Wong Youn Kim

MINUTES

1. CHAIRMAN

Dr Abdul Manaf Bin Mohamad Radzi (“Dr Chairman”) presided as Chairman of the Meeting and he welcomed all present via an online platform at the Fifth Annual General Meeting (“5th AGM”) of the Company.

2. QUORUM

Dr Chairman called the meeting to order at 10.00 a.m. upon the confirmation of the presence of a quorum by the Company Secretary.

3. OPENING

Dr Chairman introduced the Board members, Company Secretary and the Key Senior Management present at the Broadcast Venue and those participating virtually.

4. NOTICE

The notice which had been circulated to all shareholders on 18 October 2021 convening the meeting was taken as read.

5. BRIEFING ON PROCEDURES OF VIRTUAL AGM

Dr Chairman invited the Secretary to brief the meeting on the proceedings of the meeting and the voting procedures.

The Secretary, Ms Wong Youn Kim informed that the meeting would require one proposer and a seconder for each motion before putting it to the floor to vote. With a view to facilitate the flow of the meeting, the Company's Chairman and Mr Phang Nyie Lim, who are also shareholders of the Company have offered themselves to be the Proposer and Secunder for all the motions. The question and answer session and the poll will be taken at the end of the meeting.

The Company has appointed HMC Corporate Services Sdn. Bhd. as the Poll Administrator to conduct the poll by way of online voting and Usearch Management Services as Scrutineer to supervise polling process and verify the poll results. The polling process for the resolutions would be conducted upon completion of the deliberation of all items to be transacted at the Annual General Meeting.

6. AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 AND THE REPORTS OF DIRECTORS AND AUDITORS THEREON

The Audited Financial Statements ("AFS") for the financial year ended 30 June 2021 together with the Directors' and Auditors' Reports thereon, having been circulated to all the shareholders within the prescribed period, were tabled before the Meeting.

Dr Chairman informed the Meeting that the AFS was meant for discussion only as it would not require approval from the members in accordance with Section 340(1)(a) of the Companies Act, 2016. Hence, this Agenda item was not put forward for voting.

Dr Chairman then declared the Audited Financial Statements for the financial year ended 30 June 2021 have, in accordance with the Companies Act, 2016 been properly laid and received.

7. PRESENTATION KEY UPDATES OF THE GROUP BY DR' CHAIRMAN

Dr Chairman briefed the shareholders on the following key highlights and corporate developments for Nova Group for the financial year ended 30 June 2021:-

a) Financial Highlight

Under the review of financial performance of the Group, despite the challenging economic environment, Nova Group continued to perform well in the FYE 2021.

Nova Group has recorded a revenue of RM40.48 million which is a 18.1% increase over the preceding year. This is in line with higher sales for Nova House Brand products, increase in number of distributors, and overall increase in sales from existing customers.

The major revenue of 59.4% was contributed from the dietary supplements category such as Vitamin C, Vitamin E, Multivitamins and minerals products; 21.1% from the functional foods category such as Activmax and Sustinex range of products; followed by OEM at 12.8% and skin care category products at 6.7%.

Overall, dietary supplements contributed RM24.03 million or 59.4% to the total Group's revenue for FYE2021 and recorded an increase of RM5.62 million or 30.5% compared to FYE2020.

Functional food products contributed RM8.53 million or 21.1% to the total Group's revenue for FYE2021 and recorded an increase of RM3.37 million or 65.3% compared to FYE2020.

In terms of geographical coverage, 98.8% of the total Group's revenue for the FYE2021 was sales from local market and the remaining 1.2% was sales from overseas customers. Local sales recorded an increase of RM6.25 million or 18.5% when compared to FYE2020.

Nova Group managed to increase the total number of distributors distributing our products throughout Malaysia by 42.4% from 566 outlets in FYE2020 to 806 outlets in FYE2021.

These distributors include independent retail pharmacies, hospitals, and clinics. Nova Group shall continuously improve its retail market presence, including expansion of our geographical footprint through frequent visits to new potential areas to increase the number of distributors, while continuing to engage consumers through our online retail platform.

Nova Group delivered a steady performance for our financial year ended 30 June 2021. It achieved an increase in profit after tax which came in at RM14.56 million, while profit before tax grew to RM19.29 million. This is the highest profit after tax achieved since the Company listing in 2018 and barring unforeseen circumstances, the Group is positive to keep this momentum going.

The earnings per share ("EPS") for FYE2021 stood at 4.58 sen which is a 12% increase from 4.09 sen in FYE2020. A higher EPS was consistent with the increase in the profit for the year.

The Group is steadfast in our commitment to enhance value for our shareholders. This is demonstrated through our yearly dividend payments to our shareholders.

Based on Nova Group's performance, the Company declared an interim dividend of 0.60 sen per share on 9 February 2021, which was paid out on 5 March 2021. For the first time, to reward our shareholders for the support, the Board on 9 February 2021 declared a special dividend of 1.20 sen per share, equivalent to RM3.81 million, for the financial year ended 30 June 2021, thereby making a total dividend of 1.80 sen per share paid for FYE2021 up to date.

The Board has proposed a final dividend of 1.20 sen per share single tier and is pending for shareholders' approval at this 5th Annual General Meeting.

This brings the total dividend for FYE2021 to 3.00 sen per share. This will amount to a total payout of RM9.53 million, reflecting a payout ratio of 65.5% of profit after tax for FYE2021, marking the highest dividend payout since the Group's listing in 2018.

b) Key Corporate Highlights and Way Forward

On the corporate developments, during the FYE2021, Nova Group continued to drive its strategic initiatives with a focus on the fundamentals by expanding our product portfolio and reach, while enhancing cost and production efficiencies within the

Group. Nova Group have successfully launched and added 14 new products to its portfolio.

Nova Group have launched its slow carb low glycemic index (low GI) bread loaves and buns to the market earlier this year. This was launched under Nova new brand called Healthy Joy. The range of Healthy Joy breads are clinically tested to be low in GI. It is baked with heart-healthy Omega-9 oil to promote good heart health. It is a result of our five years of unrelenting research to obtain the healthiest bread formula that also tastes irresistibly good. Slow carb Low GI breads reduce the risk of diabetes and weight gain by slowing down sugar absorption. This helps to keep blood sugar levels stable. Healthy Joy is beneficial for all groups of people especially those with diabetes and weight watchers. It provides steady energy, controls body weight and craving. Now you can be assured that you and your family will always enjoy the healthiest breads everyday. The Group is also in the midst of developing more range of healthy breads including low GI croissants that will be launched into the market soon.

Another key milestone achieved in FYE2021 is the completion of transfer listing to the Main Market of Bursa Malaysia Securities Berhad. On 11 February 2021, the Company has successfully completed its transfer listing to the Main Market of Bursa Securities which marks a significant milestone in the Group's journey. This sets the stage for even greater growth for the Group moving forward.

The Company is proud to announce the successful completion of the second clinical trial for Hepar-P and the positive results obtained from the trial. The trial results demonstrated the effectiveness and safety of Hepar-P in management of Non-Alcoholic Fatty Liver Disease (NAFLD). Hepar-P is proven effective in improving liver stiffness (fibrosis) score and lowering elevated liver specific enzyme ALT in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). The results also demonstrated that Hepar-P is safe and well-tolerated. This clinical trial is under the initiative program by the Government of Malaysia. Launched on 21 September 2010, it is a comprehensive economic transformation plan to propel Malaysia's economy into high income economy. Various sectors for development have been identified and are called National Key Economic Areas (NKEA).

The Malaysian herbal industry has been marked as a new source of growth and identified as one of the entry point projects (EPP) under the agriculture new key economic areas (NKEA) in the economic transformation programme (ETP) which commenced in early 2011. The EPP1 emphasizes developing high-value herbal products backed with clinical evidence. This is a new initiative undertaken by the government and is considered as a path-breaker for the Malaysian herbal industry and the country. Nova Laboratories Sdn Bhd, the wholly-owned subsidiary of the Company, was identified as the very first anchor companies under EPP1 and awarded a research grant to begin the clinical trial on Hepar-P.

The primary objective of this trial was to assess the efficacy and safety of Hepar-P in patients with NAFLD. The clinical trial was a randomised, multi-centered, placebo-controlled, double-blind trial. The clinical trial was conducted in three hospitals in Malaysia namely; Hospital Sultanah Bahiyah in Alor Setar, Hospital Ampang, and Hospital Selayang with a total of 226 patients recruited for this trial. This trial was led by three Consultant Hepatologist and Gastroenterologist as clinical investigators while Datuk Dr Muhammad Radzi Abu Hassan, a Consultant Physician and Gastroenterologist as the national principal investigator. A total of 24 sub-investigators among which 6 sub-investigators from Hospital Sultanah Bahiyah in Alor Setar, 4 sub-investigators from Hospital Selayang, and 14 sub-investigators

from Hospital Ampang were involved in this trial. A total of 4 study coordinators from Clinical Research Malaysia (CRM), and one study coordinator from Clinical Research Centre (CRC) Hospital Sultanah Bahiyah were involved in this trial.

Fatty liver disease is the most common liver disease worldwide. It is a serious and potentially life-threatening condition and is a leading cause of liver failure and liver transplantation globally. Fatty liver may lead to liver stiffness (fibrosis) and scarring that impairs liver functions and it may progress to advanced fibrosis, cirrhosis, and liver cancer. People suffering from obesity, high levels of cholesterol, and high blood sugar are more prone to be diagnosed with fatty liver disease. The big concern about fatty liver is that it is a silent disease. Over the past three decades, Malaysia has become the fattest country in Asia, with nearly half the Malaysian adult population now overweight or obese. Along with obesity comes obesity-related diseases, including fatty liver. Fatty liver is now fast becoming a leading cause of liver cancer in Malaysia, which is the sixth most common cancer in the country.

According to a liver cancer study published by University Malaya Medical Centre (UMMC) this year, the leading cause of liver cancer was Hepatitis B at 44%, followed by fatty liver disease at 42%, Hepatitis C at 8% and alcohol at 6%. These are the signs of modern times, with an increasing number of individuals – both adults and children – having expanding waist circumference. Fatty liver is now a major health problem and has become the commonest liver disease in Malaysia. Fatty liver disease affects close to a third of the world's population (25%) according to data published in the Clinical Therapeutics Vol.43 in 2021. In 2019, the prevalence of fatty liver in Klang Valley alone has been estimated to be at 37.4% and 23% in the general Malaysian population. The most unfortunate thing is that currently there are no approved therapies for fatty liver disease.

The primary objective of this trial was to assess the efficacy and safety of Hepar-P in patients with NAFLD. A total of 226 patients above the age of 18 years and confirmed NAFLD were enrolled and administered either Hepar-P at 3,000mg (12 capsules daily) or placebo for 52 weeks. In this trial, Hepar-P clearly showed a statistically significant difference on NAFLD patients in improving liver stiffness (fibrosis) score and lowering elevated liver specific enzyme ALT compared to placebo. In liver stiffness (fibrosis) score, the statistically significant difference was reported as early as 3 months of treatment and further improved at 12 months of treatment with Hepar-P. These results provide clear evidence on the effectiveness of Hepar-P to protect against liver injuries, delay liver damage progression and support healthy liver functions in patients with NAFLD. It also reflects the specific mode of action of Hepar-P in inhibiting liver membrane oxidation from injuring the liver. As a result of this, it improves the liver stiffness score and helps in regression of liver fibrosis. It also normalises the liver specific enzyme ALT. In this trial, the intake of Hepar-P is proven to be safe and well-tolerated with no significant safety concerns. With the positive trial results, we anticipate better market acceptance and a wider use of Hepar-P especially in clinics and hospitals for liver protection and fatty liver management. Full results from this study will be submitted for future scientific publication and presentation.

The Group also intends to proceed for regulatory filing with the National Pharmaceutical Regulatory Agency (NPRA) for a therapeutic claim for the product Hepar-P. As a health and nutrition company, we at Nova are dedicated to the discovery, development, and commercialisation of novel solutions to address some of the world's most widespread, devastating, and costly chronic diseases that account for 71% of the total deaths every year globally. Nova Group strive to set the highest standard of quality in everything we do. This clinical trial underpins our core

belief in providing high-value natural products that are supported by strong scientific evidence. It is a part of our bigger mission to improve health with evidence-based products. The Company believe that this product will be a powerful tool to make the vision of a healthy liver-world a reality and help many individuals with fatty liver disease.

Moving forward, Nova Group emphasis will be on sustaining market interests by growing our products portfolio and customer base, paying close attention to consumer needs. Amidst the uncertainties and volatilities, Nova Group remains committed to meeting customer's expectations and continued expansion of the Group's capabilities to provide value-added products and services.

8. DECLARATION OF A FINAL SINGLE TIER DIVIDEND OF 1.20 SEN PER ORDINARY SHARE IN RESPECT OF THE FINANCIAL YEAR ENDED 30 JUNE 2021

After the presentation, Dr Chairman proceeded to the second (2nd) item on the agenda which was on the declaration of a final single tier dividend of 1.20 sen per ordinary share in respect of the financial year ended 30 June 2021. The proposed dividend, if approved, would be payable on 8 December 2021 to all shareholders of the Company whose names registered in the Record of Depositors at the close of business on 1 December 2021. The motion was moved to vote by poll.

9. RE-ELECTION OF DIRECTORS PURSUANT TO CLAUSE 109 OF THE COMPANY'S CONSTITUTION

The next two motions were in relation to the re-election of Dr Abdul Manaf Bin Mohamad Radzi and Mr Phang Nyie Lin as Directors of the Company. They were retiring pursuant to Clause 109 of the Company's Constitution and being eligible, had offered themselves for re-election.

a) RE-ELECTION OF DR ABDUL MANF BIN MOHAMAD RADZI AS DIRECTOR

Dr Chairman proceeded to the agenda on the re-election of Dr Abdul Manaf Bin Mohamad Radzi as a Director of the Company, who was retiring pursuant to Clause 109 of the Company's Constitution and moved the motion to vote by poll.

b) RE-ELECTION OF MR PHANG NYIE LIN AS DIRECTOR

Dr Chairman continued with the next item which was on the re-election of Mr Phang Nyie Lin as a Director of the Company, who was retiring pursuant to Clause 109 of the Company's Constitution and moved the motion to vote by poll.

10. RE-APPOINTMENT OF MESSRS MAZARS PLT AS AUDITORS OF THE COMPANY

The Chairman proceeded to the next item on the agenda to consider the re-appointment of Messrs Mazars PLT as Auditors of the Company and to authorise the Directors to fix their remuneration.

The retiring Auditors, Messrs Mazars PLT had indicated their willingness to continue in office.

He then moved the motion to vote by poll.

11. DIRECTORS' FEES OF RM216,000.00 FOR THE PERIOD FROM THE DATE OF FORTHCOMING ANNUAL GENERAL MEETING UNTIL THE NEXT ANNUAL GENERAL MEETING IN YEAR 2022

The next item on the Agenda was to approve the payment of directors' fees of RM216,000.00 for the period from the date of Annual General Meeting until the next Annual General Meeting in year 2022.

The Chairman moved the motion to vote by poll.

12. DIRECTORS' BENEFITS FOR THE PERIOD FROM THE DATE OF FORTHCOMING ANNUAL GENERAL MEETING UNTIL THE NEXT ANNUAL GENERAL MEETING IN YEAR 2022

The next item on the Agenda was to approve the payment of directors' benefits for the period from the date of forthcoming Annual General Meeting until the next Annual General Meeting in year 2022.

The Chairman moved the motion to vote by poll.

13. SPECIAL BUSINESS

(a) AUTHORITY TO ISSUE SHARES

The Meeting proceeded to consider the motion on the authority to issue shares pursuant to the Companies Act, 2016 ("General Mandate") as set out in the Notice of Annual General Meeting. The Meeting noted that the motion, if passed, would empower the Directors of the Company to allot and issue new shares in the Company from time to time provided that the aggregate number of shares to be issued pursuant to the General Mandate does not exceed 10% of the total issued share capital of the Company for the time being.

The Chairman moved the motion to vote by poll.

14. ANY OTHER BUSINESS

As no notice had been received to transact any other business, Dr Chairman put all resolutions to vote via an online platform and opened the Questions & Answer Session at 10.35 a.m.

The following questions raised by shareholders/proxies were duly replied:-

(1) Questions raised by Mr Teh Kian Lang, a shareholder of the Company

- (a) What is the status of the cosmetics industry?
- (b) The percentage of the new plant utilization?
- (c) Any door gift provided?
- (d) How is business outlook in next 6 months?
- (e) Is there a chance of top-line growth in the next 12 months?
- (f) Is the increased in raw material costs causing a pressure on margins?

Nova's Response

- (a) The Company is optimistic about the cosmetics segment, and more new products will be launching in the near future to strengthen this segment.
- (b) The utilization of new plant is approximately 60%.
- (c) There will be no door gift given. However, the Company will take note of e-door gift for the future AGM.
- (d) In the absence of unforeseen circumstances, the Company anticipates a favourable outlook since people are more health-conscious, particularly in the especially after the Covid-19 outbreak.
- (e) The Company expect a growth in the next 12 months.
- (f) The decrease in gross profit margin was mostly attributable to rising production raw material costs.

(2) Questions raised by Mr Hoy Lai Wah, a shareholder of the Company

- (a) How many clinical trials does Hepar-P need to go through?
- (b) When will Hepar-P capsules be commercialized production?

Nova's Response

- (a) Hepar-P had completed the second phase of the clinical trial.
- (b) Hepar-P is an existing product available in the market. With this clinical trial, it will add more scientific value to the product.

(3) Questions raised by Mr Tai Shih Chau, a Shareholder of the Company

- (a) How many of the 806 outlets are NWPP? In 2019, how many NWPP will there be? Has NWPP's minimum selling requirement changed over time? Is it possible to find out what the requirements are?
- (b) According to the 2021 Annual Report, there is a major customer with an RM6.9 million revenue. However, it does not appear in the 2020 Annual Return. Is there a sudden increase in sales for a specific customer?

Nova's Response

- (a) In the year 2019, the Company has a significant increase in the number of outlets participating in the NWPP programme. For this programme, there is still a target to meet.
- (b) The unexpected surge in sales is primarily owing to an increase in product demand, particularly for the immunology line of products.

(4) Questioned raised by Mr Lim Seng Chor, a proxy of Maybank Nominees (Tempatan) Sdn. Bhd.

- (a) The demand for functional medicine, homoeopathy, and natural treatments is growing rapidly around the world. Noting that there is currently a significant shortage in the world, will Nova use the chance and take a bold stance to expose its global presence in this supply chain to the current global demand trend?
- (b) The majority of the local holistic health clinics import natural therapy supplies from other countries as demand for holistic treatment increases. Hence, it is recommended the Company to expanding the list of distributors by focusing on these clinics, which use a higher volume of supplements than other clinics.
- (c) As a result of the pandemic and immunisation campaign raising public health awareness, the detox series supplements are frequently demanded. Despite the fact that it is already part of the business plan, it is advised that the Company extend products such as N-Acetyl Cysteine, Quercetin, and Liposomal technique of Vit C / Vit D3 / Glutathione, among others, where profit margins can be attractive.

Nova's response

- (a) The demand for natural nutritional and functional solutions is growing. We will undoubtedly explore this segment.
- (b) The Company will look into expanding in this sector.
- (c) The Company do have these products and the liposomal C will be available soon.

(5) Questions raised by Mr Lee Siew Ken, a shareholder of the Company

- (a) Which of Nova's products contribute the most revenue?
- (b) What is the budget for capital expenditures in 2022, and how will they be spent?
- (c) With the positive results of the clinical trial, how will the Company promote Hepar-P more aggressively in Malaysia and internationally?
- (d) Where can the 2nd clinical study report be accessed?

Nova's Response

- (a) Health supplements are still the biggest revenue contributor. Heart health, immunity and joint health product range contributes are categories that are majority contribution to the revenue.
- (b) The capital expenditure budget for 2022 is RM2.12 million, which will be used mostly to acquire plant and machinery.
- (c) For the Malaysian market, we are setting up a specialised team to focus on and promote Hepar-P to clinics and hospitals.

In terms of the international market, the Company will first concentrate on the Indonesian market, where Hepar-P is already registered.

- (d) The Company will publish the 2nd clinical study report soon.

(6) Questions raised by Mr Cheong Sian Hoe, a shareholder of the Company

It was suggested that the Company provide coupons for the purchase of the Company's products.

Nova's Response

At this moment, the Company is not distributing any vouchers to purchase the product, however, the Company will look into it in the future.

(7) Questions raised by Mr Ng Swee Kiang, a shareholder of the Company

- (a) Could you provide me a breakdown of the 806 outlets in total?

Nova's Response

- (a) Nova outlets are located all across the country. Every state has a representative who distributes Nova products. The Company is currently concentrating on ensuring that every district has a Nova distributor.

(8) Questions raised by Mr Heng Tien Yew, a shareholder of the Company

- (a) What is the revenue breakdown between herbal supplements, vitamin and mineral supplements in Nova's health supplement sales?
- (b) What is the Nova's same store sales growth trend since it has been listed?
- (c) Has the Company been able to sell to Malaysia's top three pharmacy chains such as Watson, and Caring?

Nova's Response

- (a) It is equally distributed among the product categories.
- (b) Currently, the Company does not have its own retail store. The majority of the Company's growth came from pharmacies, health food shops, clinics, and hospitals.
- (c) The focus of the company is mostly on independent retail pharmacies.

(9) Questions raised by Mr Kok Wai Keat, a shareholder of the Company

- (a) Is the company developing a COVID-prevention supplement?

Nova's Response

- (a) No. The Company offers a variety of immune-boosting products (Buffered Roselle C, Lifefit Gold, Black Cumin Oil, NovGlucan) as well as family protection items (sanitisers, face mask).

(10) Questions raised by Mr Tan Choon Kiat, a proxy of HLB Nominees (Tempatan) Sdn. Bhd.

- (a) What is the outlet's projected expansion in 2022?

Nova's Response

- (a) The Company is looking at 15% growth in distribution.

(11) Questions raised by Mr Low Keng Seng, a proxy of Kenanga Nominees (Tempatan) Sdn. Bhd.

- (a) How is the progress of registration of product in oversea market?
- (b) Any new functional food product will be launched in next year?

Nova's Response

- (a) The Company has products registered in Indonesia and Thailand.
- (b) The Company is developing and will launch more new products in this category.

(12) Questions raised by Mr Chau Jia Xian, a shareholder of the Company

- (a) Does the rise in raw material cause any huge impact to the company?
- (b) Is the management planning to expand aggressively into new markets, such as Indonesia?

Nova's Response

- (a) There is no material impact in increasing cost of raw material.
- (b) Yes. The Company has products registered in Indonesia including Hepar-P.

(13) Questions raised by Ms Wang Wei Yan, a shareholder of the Company

- (a) After Indonesia and Thailand, which countries will be focused on?

Nova's Response

- (a) The Company will concentrate on the Southeast Asian region.

(14) Questions raised by Mr Cha Ban Choon, a shareholder of the Company

- (a) What are the future development plans?

Nova's Response

- (a) The Company will continue to emphasize on sustaining market interests by growing Nova's products portfolio and customer base, paying close attention to

customer needs.

15. ANNOUNCEMENT OF POLL RESULTS

Dr Chairman called the meeting to order at 11.25 a.m. for the declaration of the following poll results:-

Ordinary Resolution 1: Declaration of a Final Single Tier Dividend of 1.20 sen per share for the financial year ended 30 June 2021 as recommended by the Directors

Resolution	For		Against	
	No. of Shares	%	No. of Shares	%
Ordinary Resolution 1	219,252,417	99.9936	14,000	0.0064

The Chairman declared that Ordinary Resolution 1 was duly carried by majority voted FOR as follows:-

“Ordinary Resolution 1

- Declaration of a Final Single Tier Dividend of 1.20 sen per ordinary share in respect of the financial year ended 30 June 2021

THAT a final single tier dividend of 1.20 sen per ordinary share in respect of the financial year ended 30 June 2021 be and is hereby approved.”

Ordinary Resolution 2: Re-election of Dr Abdul Manaf Bin Mohamed Radzi as Director

Resolution	For		Against	
	No. of Shares	%	No. of Shares	%
Ordinary Resolution 2	219,245,215	99.9936	14,102	0.0064

The Chairman declared that Ordinary Resolution 2 was duly carried by majority voted FOR as follows:-

“Ordinary Resolution 2

- Re-election of Director – Dr Abdul Manaf Bin Mohamed Radzi

THAT Dr Abdul Manaf Bin Mohamed Radzi retiring pursuant to Clause 109 of the Company’s Constitution, be re-elected as a Director of the Company.”

Ordinary Resolution 3: Re-election of Mr Phang Nyie Lin as Director

Resolution	For		Against	
	No. of Shares	%	No. of Shares	%
Ordinary Resolution 3	219,245,215	99.9936	14,102	0.0064

The Chairman declared that Ordinary Resolution 3 was duly carried by majority voted FOR as follows:-

“Ordinary Resolution 3

- Re-election of Director – Mr Phang Nyie Lin

THAT Mr Phang Nyie Lin retiring pursuant to Clause 109 of the Company’s Constitution, be

re-elected as a Director of the Company.”

Ordinary Resolution 4: Re-Appointment of Auditors

Resolution	For		Against	
	No. of Shares	%	No. of Shares	%
Ordinary Resolution 4	219,245,215	99.9936	14,102	0.0064

The Chairman declared that Ordinary Resolution 4 was duly carried by majority voted FOR as follows:-

“Ordinary Resolution 4

- Re-appointment of Messrs Mazars PLT as Auditors of the Company

THAT Messrs Mazars PLT be hereby re-appointed as the Company’s Auditors for the ensuing year **AND THAT** the Board of Directors be authorised to fix their remuneration.”

Ordinary Resolution 5: Proposed Directors’ Fees for the period from the date of forthcoming Annual General Meeting until the next Annual General Meeting in year 2022

Resolution	For		Against	
	No. of Shares	%	No. of Shares	%
Ordinary Resolution 5	219,225,715	99.9892	23,602	0.0108

The Chairman declared that Ordinary Resolution 5 was duly carried by majority voted FOR as follows:-

“Ordinary Resolution 5

- Directors’ Fees for the period from the date of forthcoming Annual General Meeting until the next Annual General Meeting in year 2022

THAT the payment of Directors’ fees of RM216,000.00 for the period from the date of forthcoming Annual General Meeting until the next Annual General Meeting in year 2022 be hereby approved.”

Ordinary Resolution 6: Proposed Directors’ Benefit for the period from the date of forthcoming Annual General Meeting until the next Annual General Meeting in year 2022

Resolution	For		Against	
	No. of Shares	%	No. of Shares	%
Ordinary Resolution 6	219,222,615	99.9878	26,702	0.0122

The Chairman declared that Ordinary Resolution 6 was duly carried by majority voted FOR as follows:-

“Ordinary Resolution 6

- Directors’ Benefits for the period from the date of forthcoming Annual General Meeting until the next Annual General Meeting in year 2022

THAT the payment of Directors’ Benefits in the form of Nova Products and Directors’ Allowances (Meeting Attendance Allowances) of up to RM15,000.00 payable to the directors for the period from the date of forthcoming Annual General Meeting until the next Annual

General Meeting in year 2022 be hereby approved.”

Ordinary Resolution 7: Authority to issue shares

Resolution	For		Against	
	No. of Shares	%	No. of Shares	%
Ordinary Resolution 7	213,625,815	97,4293	5,636,502	2.5707

The Chairman declared that Ordinary Resolution 7 was duly carried by majority voted FOR as follows:-

“Ordinary Resolution 7
- Authority to Issue Shares

THAT subject always to the Companies Act, 2016, Constitution of the Company and approvals of the relevant governmental/regulatory bodies where such approvals shall be necessary, the Directors be and are hereby authorised and empowered pursuant to Section 75 of the Companies Act, 2016 to allot and issue shares in the Company at any time until the conclusion of the next Annual General Meeting and upon such terms and conditions and for such purposes as the Directors may, in their absolute discretion, deem fit, provided that the aggregate number of shares issued pursuant to this resolution does not exceed ten percent (10%) of the total number of issued shares for the time being of the Company.

AND THAT the Directors of the Company whether solely or jointly, be authorised to complete and do all such acts and things (including executing such relevant documents) as he/she/they may consider necessary, expedient or in the interest of the Company to give effect to the aforesaid mandate.”

16. CLOSURE OF MEETING

As there was no other matter to be discussed, for which due notice had been given in accordance with the Companies Act, 2016, the meeting concluded at 11.25 a.m. with a vote of thanks to Dr Chairman and the Board of Directors.

Confirmed as a correct record,

DR ABDUL MANAF BIN MOHAMAD RADZI
CHAIRMAN
Date: 22 February 2022